A 9-year-old South African diagnosed with HIV at a month old who received antiretroviral treatment during infancy has suppressed the virus for almost 9 years.
A new study has shown that infusion of a broadly neutralizing antibody VRC01 in virally suppressed, early treated volunteers was associated with a modestly delayed rebound of HIV after interruption of antiretroviral therapy.
A monthly vaginal ring and a daily oral tablet, both containing anti-HIV drugs, were safe and acceptable in studies of adolescents, investigators reported today at the 9th IAS Conference on HIV Science in Paris. The experimental ring is designed for HIV prevention and the oral tablet is already used for this purpose in adults. Adherence to the ring was high, while adherence to the tablet was moderate and diminished when study visits became less frequent.
Study results released today by the HIV Prevention Trials Network (HPTN) show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention.
The dapivirine vaginal ring, which had been found safe and to help protect against HIV in two Phase III trials in African women, was shown to be safe and acceptable in a study of US teen girls. Regulatory approval is being sought for the ring in women ages 18-45; the new study provides data that would be needed for expanding approval to include girls under age 18, one of the highest-risk groups in Africa.
Uncircumcised men with high levels of anaerobic penile bacteria at higher risk for HIV.
A two-year clinic-based HIV testing program in Zimbabwe failed to diagnose many cases of HIV in children in the surrounding area, Dr. Victoria Simms from the London School of Hygiene & Tropical Medicine, UK, and colleagues, report in PLOS Medicine.
Initiating antiretroviral therapy (ART) on the same day as HIV testing is feasible and leads to improved retention and health outcomes, according to a trial published in PLOS Medicine.
Results from an early-stage clinical trial called APPROACH show that an investigational HIV vaccine regimen was well-tolerated and generated immune responses against HIV in healthy adults. The APPROACH findings, as well as results expected in late 2017 from another early-stage clinical trial called TRAVERSE, will form the basis of the decision whether to move forward with a larger trial in southern Africa to evaluate vaccine safety and efficacy among women at risk of acquiring HIV.
A nine-year-old South African child who was diagnosed with HIV infection at one month of age and received anti-HIV treatment during infancy has suppressed the virus without anti-HIV drugs for eight and a half years, scientists reported today at the 9th IAS Conference on HIV Science in Paris. This case appears to be the third reported instance of sustained HIV remission in a child after early, limited anti-HIV treatment.